Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib

Cytotherapy. 2010;12(1):113-5. doi: 10.3109/14653240903300666.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Blast Crisis / chemically induced
  • Blast Crisis / immunology
  • Blast Crisis / physiopathology
  • Dasatinib
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Iatrogenic Disease / prevention & control
  • Imatinib Mesylate
  • Immunosuppressive Agents / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / physiopathology
  • Male
  • Middle Aged
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • Prednisone / therapeutic use
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / adverse effects*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Remission Induction / methods
  • Thiazoles / adverse effects*
  • Thiazoles / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Immunosuppressive Agents
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • nilotinib
  • Dasatinib
  • Prednisone